<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>50</patient-age><report-id>CA-US-EMD Serono, Inc.-7188849</report-id><gender>female</gender><reactions><reaction>LIPODYSTROPHY ACQUIRED</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>REBIF</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Alercet</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Altace</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Hydrochlorothiazide</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Marvelon</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>Vitamin B12</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10070592</indication></indications><patient-age>50</patient-age><outcomes/><country>Canada</country><geo/></meta><original><ichicsr lang="en" xmlns="">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>PRO000000000000509992</messagenumb>
    <messagesenderidentifier>EMDSERONO</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125161307</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CA-US-EMD Serono, Inc.-7188849</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>2013-01-25</transmissiondate>
    <reporttype>1</reporttype>
    <serious code="1">Yes</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>2013-01-16</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>2013-01-16</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CA-Merck KGaA-7188849</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <primarysource>
      <reporterfamilyname>Unknown</reporterfamilyname>
      <reportercountry>CA</reportercountry>
      <qualification code="1">Physician</qualification>
    </primarysource>
    <sender>
      <senderorganization>US-EMD Serono, Inc.</senderorganization>
      <senderdepartment>US Product Surveillance and Quality Assurance</senderdepartment>
      <sendertitle>Dr</sendertitle>
      <sendergivename>Daryl</sendergivename>
      <senderfamilyname>Dawson</senderfamilyname>
      <senderstreetaddress>One Technology Place</senderstreetaddress>
      <sendercity>Rockland</sendercity>
      <senderstate>MA</senderstate>
      <senderpostcode>02370</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>781-681</sendertel>
      <sendertelextension>2564</sendertelextension>
      <sendertelcountrycode>+1</sendertelcountrycode>
      <senderfax>781-681</senderfax>
      <senderfaxextension>2961</senderfaxextension>
      <senderfaxcountrycode>+1</senderfaxcountrycode>
      <senderemailaddress>usps@emdserono.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>US-A-Food and Drug Administration</receiverorganization>
      <receiverdepartment>AERS</receiverdepartment>
      <receivertitle>Mr</receivertitle>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>CDER</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
      <receivercity>Rockville</receivercity>
      <receiverstate>MD</receiverstate>
      <receiverpostcode>20851</receiverpostcode>
      <receivercountrycode>US</receivercountrycode>
      <receivertel>3017709299</receivertel>
      <receivertelcountrycode>001</receivertelcountrycode>
      <receiverfax>3017706614</receiverfax>
      <receiverfaxcountrycode>001</receiverfaxcountrycode>
      <receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
    </receiver>
    <patient lang="en">
      <patientonsetage>50</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex code="2">Female</patientsex>
      <reaction>
        <primarysourcereaction lang="en">LIPODYSTROPHY ACQUIRED</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10049287</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10049287</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization code="1">suspsect</drugcharacterization>
        <medicinalproduct>REBIF</medicinalproduct>
        <drugauthorizationnumb>103780</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugstructuredosagenumb>44</drugstructuredosagenumb>
        <drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="803">Week</drugintervaldosagedefinition>
        <drugdosagetext lang="en">KIT</drugdosagetext>
        <drugdosageform normalized="injection">Injection</drugdosageform>
        <drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <actiondrug code="5">Unknown</actiondrug>
        <activesubstance>
          <activesubstancename>INTERFERON BETA-1A</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10049287</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10049287</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Alercet</medicinalproduct>
        <drugstructuredosagenumb>0.5</drugstructuredosagenumb>
        <drugstructuredosageunit code="032"/>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
        <drugdosageform normalized="tablet">Tablet</drugdosageform>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Altace</medicinalproduct>
        <drugstructuredosagenumb>2.5</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
        <drugdosageform normalized="capsule">Capsule</drugdosageform>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Hydrochlorothiazide</medicinalproduct>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
        <drugdosageform normalized="tablet">Tablet</drugdosageform>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Marvelon</medicinalproduct>
        <drugdosageform normalized="tablet">Tablet</drugdosageform>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>Vitamin B12</medicinalproduct>
        <drugdosageform normalized="injection">Injection</drugdosageform>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical>This case report of a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>in Canada was received via the Canadian Health Authority (000157485) at Merck Serono on 16 Jan 2013. A 50-year old female patient experienced <Semaphore x="3071837" class="MedDRA LLT" value="Lipodystrophy acquired" score="1.00" ID="10049287"><Semaphore x="2115323" class="Disease or Finding" value="Lipodystrophy" score="1.00" ID="C97093">lipodystrophy </Semaphore>acquired </Semaphore>while being treated with <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.87" ID="249401">Rebif</Semaphore>.The event <Semaphore x="3071837" class="MedDRA LLT" value="Lipodystrophy acquired" score="1.00" ID="10049287"><Semaphore x="2115323" class="Disease or Finding" value="Lipodystrophy" score="1.00" ID="C97093">lipodystrophy </Semaphore>acquired </Semaphore>was assessed as medically significant by the Company.No relevant <Semaphore x="2210075" class="Procedure" value="Medical Research Council Dyspnea Scale" score="1.00" ID="C21157">medical history was reported</Semaphore>.The patient's concomitant medications included Alercet (<Semaphore x="323473" class="Medicine" value="Cetirizine" score="0.49" ID="242103">cetirizine</Semaphore>) tablet at the dosage of 0.5 dosage form once a day, <Semaphore x="86752" class="Medicine" value="Altace" score="0.49" ID="252206">Altace </Semaphore>(<Semaphore x="1119676" class="Medicine" value="Ramipril" score="0.49" ID="258414">ramipril</Semaphore>) capsule at the dosage of 2.5 mg once a day, <Semaphore x="675434" class="Medicine" value="Hydrochlorothiazide" score="0.49" ID="270905">hydrochlorothiazide </Semaphore>tablet at the dosage of 25 mg once a day, Marvelon (<Semaphore x="444933" class="Medicine" value="Desogestrel" score="0.49" ID="249283">desogestrel</Semaphore>, <Semaphore x="548016" class="Medicine" value="Ethinyl Estradiol" score="0.49" ID="267939">ethinyl <Semaphore x="1904499" class="Procedure" value="Estradiol Measurement" score="1.00" ID="C74782">estradiol</Semaphore></Semaphore>) 28 tablet and <Semaphore x="2692070" class="Procedure" value="Vitamin B12 Measurement" score="1.00" ID="C64817">vitamin B12 </Semaphore><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection</Semaphore>, all administered for an unknown indication.The patient received <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.87" ID="249401">Rebif </Semaphore>(<Semaphore x="735013" class="Medicine" value="Interferon beta-1a" score="0.74" ID="273567"><Semaphore x="735630" class="Medicine" value="Interferon-beta" score="0.49" ID="268564">interferon beta </Semaphore>1a</Semaphore>) subcutaneously at the dosage of 44 mcg three times a week subcutaneously from an unknown date for an unknown indication.On an unspecified date, the patient experienced <Semaphore x="3071837" class="MedDRA LLT" value="Lipodystrophy acquired" score="1.00" ID="10049287"><Semaphore x="2115323" class="Disease or Finding" value="Lipodystrophy" score="1.00" ID="C97093">lipodystrophy </Semaphore>acquired</Semaphore>. At the time of reporting, action taken with <Semaphore x="1121746" class="Medicine" value="Rebif" score="0.87" ID="249401">Rebif </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>was not reported.At the time of reporting, the event had not resolved.The reporter did not provide any causality <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment</Semaphore>.</narrativeincludeclinical>
        <sendercomment lang="en">Lipodystrophy acquired [Lipodystrophy acquired] in a 50-year-old female patient while being treated with Rebif for an unknown indication. 
Temporal relationship: compatible. Latency: not assessable (Rebif start date and event onset date not provided). Dechallenge: not applicable (action taken with Rebif therapy not reported). 
Evaluation by reporter (physician): not reported. 
Evaluation by company: In the absence of sufficient information to fully assess the case, lipodystrophy acquired has been assessed as causally related to Rebif. 
Lipodystrophy acquired is unlisted for Rebif as per reference safety information.

Follow-up information has been requested regarding Rebif therapy details (start date, indication, action taken), medical history, AE onset date, corrective measures taken, relevant investigations and outcome.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr></original></faers>